Home » Stocks » Ascendis Pharma A/S

Ascendis Pharma A/S (ASND)

Stock Price: $141.00 USD 0.51 (0.36%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 6.77B
Revenue (ttm) 15.79M
Net Income (ttm) -257.40M
Shares Out 53.17M
EPS (ttm) -3.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $141.00
Previous Close $140.49
Change ($) 0.51
Change (%) 0.36%
Day's Open 141.00
Day's Range 139.35 - 142.49
Day's Volume 82,715
52-Week Range 90.06 - 158.93

More Stats

Market Cap 6.77B
Enterprise Value 6.10B
Earnings Date (est) Aug 26, 2020
Ex-Dividend Date n/a
Shares Outstanding 53.17M
Float 39.92M
EPS (basic) n/a
EPS (diluted) -3.87
FCF / Share -4.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.91M
Short Ratio 5.82
Short % of Float n/a
Beta 0.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 428.46
PB Ratio 12.01
Revenue 15.79M
Operating Income -267.68M
Net Income -257.40M
Free Cash Flow -213.81M
Net Cash 662.92M
Net Cash / Share 13.81
Gross Margin 100.00%
Operating Margin -1,695.10%
Profit Margin -1,630.00%
FCF Margin -1,353.98%
ROA -22.02%
ROE -35.99%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 11
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$184.60*
(30.92% upside)
Low
161
Current: $141.00
High
224
Target: 184.60
*Average 12-month USD price target from 11 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year20192018201720162015201420132012
Revenue13.3810.581.534.618.1213.9820.4115.58
Revenue Growth26.41%591.57%-66.78%-43.26%-41.94%-31.48%30.96%-
Gross Profit13.3810.581.534.618.1213.9820.4115.58
Operating Income-227-155-112-72.92-41.83-11.995.281.51
Net Income-218-130-124-68.51-32.92-9.664.081.25
Shares Outstanding46.5141.0933.6326.5623.7711.4110.808.41
Earnings Per Share-4.69-3.17-3.68-2.58-1.39-0.850.320.14
EPS Growth------128.57%-
Operating Cash Flow-176-139-95.10-60.18-43.47-18.406.31-0.65
Capital Expenditures-5.16-2.65-0.94-0.67-1.04-0.41-1.20-0.29
Free Cash Flow-181-141-96.04-60.85-44.51-18.815.12-0.94
Cash & Equivalents59827819518012050.1719.4314.54
Total Debt36.62------0.21
Net Cash / Debt56127819518012050.1719.4314.32
Assets67731921119013258.6726.7025.41
Liabilities79.6238.9223.7713.4611.4512.8620.4023.85
Book Value59728018717712045.816.301.56
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Ascendis Pharma A/S
Country Denmark
Employees 330
CEO Jan Møller Mikkelsen

Stock Information

Ticker Symbol ASND
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ASND
IPO Date January 28, 2015

Description

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.